Homogeneous recombinant Mycobacterium tuberculosis shikimate dehydrogenase production: an essential step towards target-based drug design.

Autor: Rodrigues Vda S Jr; Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS 90619-900, Brazil., Basso LA, Santos DS
Jazyk: angličtina
Zdroj: International journal of biological macromolecules [Int J Biol Macromol] 2009 Aug 01; Vol. 45 (2), pp. 200-5. Date of Electronic Publication: 2009 May 20.
DOI: 10.1016/j.ijbiomac.2009.05.003
Abstrakt: Mycobacterium tuberculosis shikimate dehydrogenase (MtbSD) catalyzes the forth reaction in the shikimate pathway. Here we describe production of K69A, K69H, K69I, K69Q, D105A, and D105N mutant proteins. Screening of several conditions was performed to optimize MtbSD production yield, and an improved purification protocol to obtain homogeneous MtbSD is presented. The rational design of new antitubercular drugs hinges on the availability of M. tuberculosis proteins. Our results show that optimization of expression, disruption, and purification protocols resulted in a higher yield of functional MtbSD enzyme.
Databáze: MEDLINE